Investor Centre
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
134.25p
-1.25p
at 23-04-2021 3:37:00
15 minute delayed share price from London Stock Exchange provided by Euroland.